Disc Medicine (NASDAQ:IRON) Announces Quarterly Earnings Results

Disc Medicine (NASDAQ:IRON) posted its quarterly earnings data on Thursday. The company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17, FiscalAI reports.

Disc Medicine Trading Up 7.5%

NASDAQ IRON traded up $5.54 during mid-day trading on Thursday, reaching $79.21. 374,866 shares of the stock were exchanged, compared to its average volume of 598,085. The stock has a market cap of $3.02 billion, a P/E ratio of -11.97 and a beta of 0.97. The company has a debt-to-equity ratio of 0.04, a current ratio of 24.00 and a quick ratio of 24.00. Disc Medicine has a one year low of $40.00 and a one year high of $99.50. The stock has a 50 day simple moving average of $72.29 and a 200-day simple moving average of $69.63.

Insider Activity at Disc Medicine

In other news, CEO John D. Quisel sold 33,000 shares of the firm’s stock in a transaction that occurred on Monday, July 13th. The shares were sold at an average price of $74.96, for a total transaction of $2,473,680.00. Following the completion of the sale, the chief executive officer owned 226,064 shares of the company’s stock, valued at $16,945,757.44. This trade represents a 12.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Rahul Khara sold 1,649 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total value of $123,675.00. Following the transaction, the insider directly owned 52,173 shares in the company, valued at approximately $3,912,975. This trade represents a 3.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 105,712 shares of company stock worth $7,597,536 in the last 90 days. Corporate insiders own 3.76% of the company’s stock.

Institutional Trading of Disc Medicine

A number of large investors have recently bought and sold shares of IRON. Persistent Asset Partners Ltd purchased a new position in Disc Medicine in the 4th quarter valued at approximately $141,000. Russell Investments Group Ltd. boosted its holdings in shares of Disc Medicine by 15,137.5% in the third quarter. Russell Investments Group Ltd. now owns 2,438 shares of the company’s stock worth $161,000 after acquiring an additional 2,422 shares during the period. Virtus Investment Advisers LLC grew its position in shares of Disc Medicine by 34.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 2,897 shares of the company’s stock valued at $230,000 after purchasing an additional 739 shares in the last quarter. AlphaCentric Advisors LLC purchased a new position in shares of Disc Medicine in the fourth quarter valued at $298,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Disc Medicine by 383.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,975 shares of the company’s stock valued at $211,000 after purchasing an additional 3,152 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Morgan Stanley boosted their price target on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Wedbush reissued an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Finally, Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus target price of $104.44.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.